Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Takes Firehawk® to Encore Seoul 2018 in Korea


Seoul, Korea – From September 12 to 14, the 12th Annual Symposium of the Endovascular & Coronary Revascularization in Seoul (Encore Seoul 2018) took place in Seoul, Korea. More than 3,000 cardiologists from 18 countries were invited to attend the event, conducting comprehensive exchanges and discussions on the latest progress of the advanced therapies and clinical researches in the field of cardiology. Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") was present throughout the symposium and held an exclusive Firehawk® satellite conference, which showcased the latest clinical data and scientific results of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®").
On September 13, Professor Niels Van Royen from Radboud University Medical Center, Netherlands, who was one of the investigators of the Firehawk® TARGET AC clinical study, introduced during the Featured Lecture session the latest clinical data of Firehawk®, which was published on the website of the world leading medical journal The Lancet on September 3 UK time. This is the first time that clinical data from a China manufactured drug eluting stent has been published in The Lancet since its first publication nearly 200 years ago.
During the symposium, Professor Hyo-Soo Kim, who was one of the directors of Encore Seoul 2018, along with the experts from other countries, spoke highly of the innovative process of Firehawk® and the rigorous design of the TARGET AC study. Professor Justin Davies from Hammersmith Hospital, UK, Professor Giulio Stefanini from Humanitas Research Hospital, Italy, and Ariel Finkelstein from Tel Aviv Medical Center, Tel-Aviv, Israel had a heated discussion about Firehawk® and praised the product and the related research results. Professor Hyo-Soo Kim said in the concluding remark that the in-groove design of the new generation coronary stent Firehawk® demonstrates evident advantages and delivers excellent clinical outcome. He added that he expected the ongoing Firehawk® clinical trial in Korea to achieve outstanding results.
On September 14, the Firehawk® satellite conference happened as scheduled with every seat occupied and Professor Yang-Soo Jang, another director of Encore Seoul 2018 as guest moderator. During the event, Professor Niels van Royen spoke about the Firehawk® TARGET AC clinical study results and the OCT and QCA sub-study results. The participating prominent cardiologists in Korea, including Professor Jung Hwan Kim, Professor Ki Seok Kim and Professor Jae Woong Cho had a heated scientific discussion with Professor Niels van Royen.
Afterwards, Professor Chun-Wei Lee from Mackay Memorial Hospital, Taiwan and Professor Seung-Woon Rha from Korea University Guro Hospital spoke about the clinical experience of the application of Firehawk® in the complex lesions including the opening of the culprit vessel, CTO lesion and acute heart failure, and they were full of praise for the performance of Firehawk®. At the end of the satellite conference, Professor Seung-Woon Rha introduced the ongoing Firehawk® clinical study in Korea, adding that he hoped Firehawk® would benefit more Korean patients in the future. He also expected MicroPort® to successfully develop the more outstanding stent products of new generation.
As one of the most important markets in Asia-Pacific, the medical device market in Korea is very promising. Firehawk® entered the Korean market in 2017, with its first local implantation completed in March 2018. With more high-quality clinical data expected to be published and the progress of the Firehawk® clinical study in Korea, MicroPort® will continuously further explore the local market, so as to provide the patients with more comprehensive and best, yet affordable, medical solutions.


About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Orthopedics Holds First University of Hong Kong - Shenzhen Hospital Total Knee Arthroplasty Technique (TKA) Advancement Course
[Next]:MicroPort® Appears at China Medical Devices Design & Startups Competition & Global Device Week (2018)